Research programme: cancer immunotherapies - Geneos Therapeutics
Latest Information Update: 28 Mar 2023
At a glance
- Originator Geneos Therapeutics
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunogenetic modulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer